Neuphoria Therapeutics Inc.
Income Statement
| Line Item | Mar 2025 | Dec 2024 |
|---|---|---|
| Revenue | $15.0M | $662.7K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $1.6M | $1.7M |
| SG&A Expense | $1.4M | $2.6M |
| Operating Income | $12.0M | $-3.7M |
| Operating Margin | 79.8% | -558.8% |
| Interest Expense | — | — |
| Pretax Income | $11.2M | $-1.9M |
| Income Tax Expense | $-81.2K | $11.6K |
| Net Income | $11.3M | $-1.9M |
| Net Margin | 75.1% | -293.2% |
| EPS (Basic) | $6.55 | $-1.23 |
| EPS (Diluted) | $6.55 | $-1.79 |
| Shares Outstanding (Basic) | 1.7M | 1.6M |
| Shares Outstanding (Diluted) | 1.7M | 1.6M |
| Dividends Per Share | — | — |